EFFICACY OF NADOFARAGENE FIRADENOVEC-VNCG FOR PATIENTS WITH BACILLUS CALMETTE-GUERIN-UNRESPONSIVE NON-MUSCLE-INVASIVE BLADDER CANCER: FINAL RESULTS FROM A PHASE 3 TRIAL

被引：0
|
作者：
Boorjian, Stephen A.
Narayan, Vikram M.
Konety, Badrinath R.
Master, Viraj A.
Shore, Neal D.
Kamat, Ashish M.
Bivalacqua, Trinity J.
Kates, Max R.
Montgomery, Jeffrey S.
Lerner, Seth P.
Crispen, Paul L.
Steinberg, Gary D.
Agarwal, Piyush K.
Schuckman, Anne K.
Svatek, Robert S.
Lane, Brian R.
Karsh, Lawrence I.
Bjurlin, Marc A.
Brown, Gordon A.
Lotan, Yair
Inman, Brant A.
Williams, Michael B.
Cookson, Michael S.
Chang, Sam S.
Kim, Eric H.
Sankin, Alexander I.
Rehm, Dorte
Jakobsen, Jorn S.
Juul, Kristian
Dinney, Colin P. N.
机构：
来源：
JOURNAL OF UROLOGY | 2024年 / 211卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
PD48-01
引用
收藏
页码：E987 / E987
页数：1
相关论文
共 50 条
  • [31] The Role of Bacillus Calmette-Guerin in the Treatment of Non-Muscle-Invasive Bladder Cancer
    Gontero, Paolo
    Bohle, Andreas
    Malmstrom, Per-Uno
    O'Donnell, Michael A.
    Oderda, Marco
    Sylvester, Richard
    Witjes, Fred
    EUROPEAN UROLOGY, 2010, 57 (03) : 410 - 429
  • [32] Efficacy and toxicity of intravesical Bacillus Calmette-Guerin therapy in elderly patients with non-muscle-invasive bladder cancer
    Matsuoka, Yuki
    Taoka, Rikiya
    Kohashiguchi, Kana
    Tohi, Yoichiro
    Miyauchi, Yasuyuki
    Kato, Takuma
    Tsunemori, Hiroyuki
    Ueda, Nobufumi
    Sugimoto, Mikio
    CURRENT UROLOGY, 2021, 15 (01) : 16 - 21
  • [33] Correction to: Nadofaragene firadenovec in high-risk Bacillus Calmette Guérin unresponsive non-muscle invasive bladder cancer: a profile of its use
    Tina Nie
    Drugs & Therapy Perspectives, 2024, 40 : 137 - 137
  • [34] Antiadenovirus Antibodies Predict Response Durability to Nadofaragene Firadenovec Therapy in BCG-unresponsive Non-muscle-invasive Bladder Cancer: Secondary Analysis of a Phase 3 Clinical Trial
    Mitra, Anirban P.
    Narayan, Vikram M.
    Mokkapati, Sharada
    Miest, Tanner
    Boorjian, Stephen A.
    Alemozaffar, Mehrdad
    Konety, Badrinath R.
    Shore, Neal D.
    Gomella, Leonard G.
    Kamat, Ashish M.
    Bivalacqua, Trinity J.
    Montgomery, Jeffrey S.
    Lerner, Seth P.
    Busby, J. Erik
    Poch, Michael
    Crispen, Paul L.
    Steinberg, Gary D.
    Schuckman, Anne K.
    Downs, Tracy M.
    Svatek, Robert S.
    Mashni, Joseph
    Lane, Brian R.
    Guzzo, Thomas J.
    Bratslavsky, Gennady
    Karsh, Lawrence, I
    Woods, Michael E.
    Brown, Gordon A.
    Canter, Daniel
    Luchey, Adam
    Lotan, Yair
    Krupski, Tracey
    Inman, Brant A.
    Williams, Michael B.
    Cookson, Michael S.
    Keegan, Kirk A.
    Andriole, Gerald L.
    Sankin, Alexander, I
    Boyd, Alan
    O'Donnell, Michael A.
    Philipson, Richard
    Yla-Herttuala, Seppo
    Sawutz, David
    Parker, Nigel R.
    McConkey, David J.
    Dinney, Colin P. N.
    EUROPEAN UROLOGY, 2022, 81 (03) : 223 - 228
  • [35] LONG-TERM COST-EFFECTIVENESS OF NADOFARAGENE FIRADENOVEC AND OPORTUZUMAB MONATOX FOR TREATMENT OF BACILLUS CALMETTE-GUERIN (BCG)-UNRESPONSIVE, NON-MUSCLE INVASIVE BLADDER CANCER (NMIBC)
    Joshi, M.
    Atlas, S. J.
    Rind, D. M.
    Beinfeld, M.
    McKenna, A.
    Patel, S.
    Chapman, R. H.
    Pearson, S.
    Touchette, D.
    VALUE IN HEALTH, 2021, 24 : S33 - S33
  • [36] Efficacy of Intravesical Nadofaragene Firadenovec for Patients With Bacillus Calmette-Guérin-Unresponsive Nonmuscle-Invasive Bladder Cancer: 5-Year Follow-Up From a Phase 3 Trial
    Narayan, Vikram M.
    Boorjian, Stephen A.
    Alemozaffar, Mehrdad
    Konety, Badrinath R.
    Shore, Neal D.
    Gomella, Leonard G.
    Kamat, Ashish M.
    Bivalacqua, Trinity J.
    Montgomery, Jeffrey S.
    Lerner, Seth P.
    Busby, Joseph E.
    Poch, Michael
    Crispen, Paul L.
    Steinberg, Gary D.
    Schuckman, Anne K.
    Downs, Tracy M.
    Mashni, Joseph
    Lane, Brian R.
    Guzzo, Thomas J.
    Bratslavsky, Gennady
    Karsh, Lawrence I.
    Woods, Michael E.
    Brown, Gordon
    Canter, Daniel
    Luchey, Adam
    Lotan, Yair
    Inman, Brant A.
    Williams, Michael B.
    Cookson, Michael S.
    Chang, Sam S.
    Sankin, Alexander I.
    O'Donnell, Michael A.
    Sawutz, David
    Philipson, Richard
    Parker, Nigel R.
    Yla-Herttuala, Seppo
    Rehm, Dorte
    Jakobsen, Jorn S.
    Juul, Kristian
    Dinney, Colin P. N.
    JOURNAL OF UROLOGY, 2024, 212 (01): : 74 - 86
  • [37] Smoking Reduces the Efficacy of Intravesical Bacillus Calmette-Guerin Immunotherapy in Non-muscle-invasive Bladder Cancer
    Rink, Michael
    Xylinas, Evanguelos
    Babjuk, Marko
    Pycha, Armin
    Karakiewicz, Pierre I.
    Novara, Giacomo
    Dahlem, Roland
    Shariat, Shahrokh F.
    EUROPEAN UROLOGY, 2012, 62 (06) : 1204 - 1206
  • [38] Safety and efficacy of intravesical nadofaragene firadenovec for patients with high-grade, BCG unresponsive nonmuscle invasive bladder cancer (NMIBC): Results from a phase III trial
    Boorjian, Stephen A.
    Dinney, Colin P. N.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [39] A need for clear definitions and improved management for Bacillus Calmette-Guerin-unresponsive non-muscle invasive bladder cancer in Asia-Pacific
    Lee, Lui Shiong
    Kanesvaran, Ravindran
    Kikuchi, Eiji
    Nishiyama, Hiroshi
    Ku, Ja Hyeon
    Lin Tzu-Ping
    Nishiyama, Hiroyuki
    Ng, Chi Fai
    Ng, Junice Yi Siu
    Poon, Darren
    Seo, Ho Kyung
    Spiteri, Carmel
    Tan, Ee Min
    Tran, Ben
    Tsai, Yuh-Shyan
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2023, 19 : 55 - 56
  • [40] Letter: Efficacy of Intravesical Nadofaragene Firadenovec for Patients With Bacillus Calmette-Guérin-Unresponsive Nonmuscle-Invasive Bladder Cancer: 5-Year Follow-Up From a Phase 3 Trial
    Meeks, Joshua J.
    JOURNAL OF UROLOGY, 2024, 212 (04): : 623 - 624
12345